Drugs & Targets TESARO, Genentech to study Zejula with anti-PD-L1 agent, MEK inhibitor in ovarian cancer June 15, 2018Vol.44 No.24
Drugs & Targets FDA approves Venclexta with rituximab as a fixed duration treatment for CLL or SLL after one prior therapy June 15, 2018Vol.44 No.24
Drugs & Targets FDA, EMA accept application for talazoparib in metastatic breast cancer with inherited BRCA mutation June 15, 2018Vol.44 No.24
Drugs & Targets FDA approves Doptelet for thrombocytopenia in chronic liver disease May 25, 2018Vol.44 No.21
Drugs & Targets Foundation Medicine, Merck establish immuno-oncology companion diagnostics collaboration May 25, 2018Vol.44 No.21
Drugs & TargetsFree FDA approves first epoetin alfa biosimilar for the treatment of anemia May 18, 2018Vol.44 No.20
Drugs & Targets FDA approves Darzalex for newly diagnosed multiple myeloma patients who are transplant ineligible May 11, 2018Vol.44 No.19
Drugs & Targets Lynparza approved by EMA for epithelial ovarian, fallopian tube or primary peritoneal cancer May 11, 2018Vol.44 No.19
